Biosimilars Industry Urges Improved UK Evaluation Process
Follows ‘Milestone’ NICE Decision On Use Of Biosimilars For Moderate Arthritis
Executive Summary
A more efficient system to pave a path to market for biosimilars is needed in the UK, the British Biosimilars Association has urged, as it welcomed recent moves to broaden the use of adalimumab, etanercept and infliximab for treating moderate as well as severe rheumatoid arthritis.